ABSTRACT
BACKGROUND
Asthma is a chronic inflammatory airway disease, characterized clinically by wheezing and intermittent dry coughing at night, and confirmed by documenting reversi ble airflow obstruction or airway hyperresponsiveness. The global prevalence of physician-diagnosed asthma, clinical/ treated asthma, and wheezing in adults was 4.3, 4.5, and 8.6% respectively, and prevalence vary as much as 21-fold among the 70 countries. There have been multiple reports of association between vitamin D deficiency and diseases, such as cancer, depression, cardiovascular diseases, diabetes, multiple sclerosis, osteoporosis, fertility, and asthma. 3, 4 There are few studies that show a negative association between vitamin D levels and asthma. 4 The linkage between VDR polymorphisms on chromosome 12 and the diagnosis of asthma has been reported. 3 Recent studies in adult and children found a higher prevalence of hypovitaminosis D in asthmatic individuals than in the normal population. In addition, low vitamin D levels are associated with higher asthma severity and worse pulmonary function. 4, 5 In asthmatic children, patients with vitamin D deficiency demonstrated increased airway hyperresponsiveness and corticosteroid requirements. In asthmatic children and adults, serum 25-hydroxyvitamin D levels less than 30 ng/ml have been linked to airway hyperresponsiveness, impaired lung function, increased exacerbation frequency, and reduced corticosteroid responsiveness. [6] [7] [8] [9] Vitamin D has been hypothesized to increase glucocorticoid response in patients with asthma. Greater lung function is associated with higher vitamin D levels with a 22.7 (± 9.3) ml (mean ± SE) increase in forced 
RESULTS

Inclusion Criteria
The studies included were randomized controlled trials, in which vitamin D supplementation was compared with placebo/no supplementation in patients with asthma (moderateto severe) diagnosed in accordance with Global Initiative for Asthma (GINA) guidelines. The inclusion of studies was not restricted by the dose of vitamin D received, concomitant use of corticosteroids (oral/inhaled) for treatment of asthma, and language of publication.
Objectives of the Study
The primary objective of the review was to determine the evidence supporting the role of vitamin D in decreasing the number of participants with acute exacerbations. The secondary objectives were improvement in the quality of life questionnaire and adverse events reported to be related to vitamin D supplementation.
Search Methods for identification of Studies
We attempted to identify all relevant studies, regardless of language or publication status (published, unpublished, in press, on-going). We searched the following databases: PubMed, Ovid, Embase, and Cochrane Central e-Appendix 1.
We also checked reference lists of all primary studies and review articles, and searched for errata or retractions from the included studies. We also manually searched index Medicus, CTRI, and ClinicalTrials.gov for any ongoing studies and snowball mathod for the manual searching.
Selection of Studies
Two authors independently screened the titles and abstracts of all the potential studies, removed the duplicates and coded them as "retrieve" (potentially eligible) or "do not retrieve" (not eligible). The retrieved full texts were then screened for inclusion and multiple reports/articles, if any, for the same study were collated. The reasons for exclusion of the ineligible studies were recorded. Any disagreements were resolved through discussion with the arbiter.
Data Analysis
Data were analyzed using RevMan software (version 5.0.2). GRADEpro software developed by Grading of recommendations assessment, development and evaluation (GRADE) working group was used to grade the evidence as low, moderate, or high quality. 12 Continuous outcomes were presented as mean differences (MDs) with 95% confidence interval (CI) and dichotomous outcomes were presented as odds ratio (OR) with 95% CI. A meta-analysis was performed using a fixed-effect model unless there was evidence of heterogeneity (clinical and statistical) of effects across studies. We used Cochrane criteria to assess the risk of bias (quality) in the clinical studies. 13 Heterogeneity was interpreted based on thresholds as identified in The Cochrane Handbook for Systematic Reviews of Interventions.
14 We estimated statistical heterogeneity among studies using the chi-square test statistic and in turn used the result to calculate the heterogeneity statistics. 14 (Prospero registration number: CRD42014013619).
Overview of Included Studies
Out of 469 records/studies identified through database searching and 14 additional records/studies, through other sources, 133 records were removed as duplicates. The remaining 350 records were screened for titles and abstracts. Nine studies were extracted as full-text articles. Four studies were excluded (two were nonrandomized controlled trials, 15, 16 one was a murine study, 17 and one reported outcomes not relevant to the inclusion criteria 18 ). Finally, five studies were included in the systematic review (Flow Chart 1). This systematic review was conducted in accordance with the guidelines of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. 19 Two review authors independently extracted the data from included studies and noted the characteristics of included studies ( Table 1) . Risk of bias graph was also prepared for the included studies (Graph 1). The minimum dose of total cholecalciferol supplemented was 90,000 IU in 24 weeks and maximum (Table 1) . Five studies assessed the number of participants with asthma exacerbations as a primary outcome. [20] [21] [22] [23] [24] In children, three studies had participants less than 18 years of age (n = 482). [21] [22] [23] The number of participants with asthma exacerbations (any severity) in children (<18 years of age) was significantly reduced in the vitamin D supplemented group (OR:0.23, 95% CI:0.12-0.43). In adults (>18 years age), the number of participants with exacerbations was not significantly reduced in the vitamin D supplemented group (OR:0.89, 95% CI:0.47-1.68) (n = 630). 20, 24 The overall pooled effect showed a significant reduction in number of participants with asthma exacerbation in vitamin D supplemented group (OR:0.45, 95% CI:0.22-0.93, five trials; moderate-quality evidence; Tables 2 and 3) . There were no studies that reported data on quality of life questionnaire. A total of 23 serious adverse events in 20 participants and 1283 nonserious adverse events in 240 participants were reported by the single study. 24 The quality of the evidence was assessed according to GRADE using GRADEpro software (Table 3) .
DISCUSSION
Summary of Results
This systematic review and meta-analysis on the evidence of vitamin D supplementation in patients with moderate to severe asthma has shown its effect on various aspects of asthma. Vitamin D supplementation has significantly reduced the asthma exacerbations in children. [21] [22] [23] However, in adults, two studies 20, 24 did not report any reduction in the number of participants with asthma exacerbations. There were no studies that reported quality of life questionnaire. There were 23 serious adverse events and a total of 1283 nonserious adverse events reported by a single study.
24
Heterogeneity and Sensitivity Analysis
Heterogeneity was considerably higher in the trials included to determine asthma exacerbations in those >18 years of age. Thus, the sensitivity analysis was done by using the random effect model. The higher heterogeneity was due to a single study done in children, having higher effect size than the other four included studies in children having low effect size (Table 4) . 22 The results of our systematic review on asthma exacerbations were similar in comparison to a previous meta-analysis, but a subgroup analysis done in our review is not reported by the previous meta-analysis. 25 The results of the meta-analysis on exacerbation were not documented by the recent systematic review that included observational studies. The moderate quality of GRADE reported in our systematic review is due to significant attrition shown by two of the included studies 22, 23 and no description of the method of randomization and allocation concealments in one included study. 22 The GRADE analysis done in our review is not demonstrated by previous systematic reviews. 25, 26 
Strengths and Limitations of Review
The strength of the present systematic review lies in the inclusion of studies that report the outcomes in both children and adult asthmatic individuals. Our study reported the reduction in number of participants with asthma exacerbations in children, with the similar findings documented by the previous review. 27 However, there is no reduction in adult population and is not reported by previous review. 27 There are no studies that focus on the secondary outcome of the quality of life in the included studies. The data from the ongoing trials could not be added due to nondisclosure of results. The pooled sample size of the included trials is low, leading to a higher heterogeneity. Based on the results from our systematic review, it is recommended to design future randomized trials with primarily analyzing baseline levels of vitamin D, and then supplementing with higher doses of vitamin D for the deficient ones for a fixed duration of time.
CONCLUSION
This systematic review supports the role of vitamin D in reducing the number of asthma exacerbations in children but not in adults.
